Norway’s Furst Medical Laboratory, a private laboratory specializing in medical biochemistry and pathology, has acquired Norwegian fish health company PatoGen.
Furst, held in part by Ferd, the investment vehicle behind seafood private equity group Broodstock Capital, announced Wednesday it snapped up 100 percent of the shares but will continue to develop PatoGen as a leading provider of preventive and diagnostic analysis to the growing aquaculture industry.
Furst is among the largest medical laboratory service providers in Northern Europe providing services for medical doctors and specialists throughout Norway.
